302 related articles for article (PubMed ID: 24756804)
21. Lenalidomide and its role in the management of multiple myeloma.
Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
[TBL] [Abstract][Full Text] [Related]
22. Cyclophosphamide addition to pomalidomide/dexamethasone is not necessarily associated with universal benefits in RRMM.
Park H; Byun JM; Yoon SS; Koh Y; Yoon SW; Shin DY; Hong J; Kim I
PLoS One; 2022; 17(1):e0260113. PubMed ID: 35085238
[TBL] [Abstract][Full Text] [Related]
23. Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone.
Morgan G; Palumbo A; Dhanasiri S; Lee D; Weisel K; Facon T; Delforge M; Oriol A; Zaki M; Yu X; Sternas L; Jacques C; Akehurst R; Offner F; Dimopoulos MA
Br J Haematol; 2015 Mar; 168(6):820-3. PubMed ID: 25403264
[TBL] [Abstract][Full Text] [Related]
24. [Novel agents in multiple myeloma treatment].
Ito S
Rinsho Ketsueki; 2015 Oct; 56(10):2066-73. PubMed ID: 26458446
[TBL] [Abstract][Full Text] [Related]
25. Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide.
Das DS; Ray A; Song Y; Richardson P; Trikha M; Chauhan D; Anderson KC
Br J Haematol; 2015 Dec; 171(5):798-812. PubMed ID: 26456076
[TBL] [Abstract][Full Text] [Related]
26. Pomalidomide: first global approval.
Elkinson S; McCormack PL
Drugs; 2013 May; 73(6):595-604. PubMed ID: 23572409
[TBL] [Abstract][Full Text] [Related]
27. Pooled analysis of the reports of pomalidomide after failure of lenalidomide and (or) bortezomib for multiple myeloma.
Sheng Z; Liu G
Hematol Oncol; 2016 Jun; 34(2):102-7. PubMed ID: 25643940
[TBL] [Abstract][Full Text] [Related]
28. [Successful treatment with thalidomide-combined therapy in an amyloidosis-complicated multiple myeloma patient refractory to bortezomib, lenalidomide, and pomalidomide].
Aoki Y; Hayashi T; Ikeda H; Ishida T
Rinsho Ketsueki; 2018; 59(3):275-280. PubMed ID: 29618684
[TBL] [Abstract][Full Text] [Related]
29. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation.
Streetly MJ; Gyertson K; Daniel Y; Zeldis JB; Kazmi M; Schey SA
Br J Haematol; 2008 Apr; 141(1):41-51. PubMed ID: 18324965
[TBL] [Abstract][Full Text] [Related]
30. Pomalidomide therapy for myeloma.
Schey S; Ramasamy K
Expert Opin Investig Drugs; 2011 May; 20(5):691-700. PubMed ID: 21413906
[TBL] [Abstract][Full Text] [Related]
31. Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide.
Mariz JM; Esteves GV
Curr Opin Oncol; 2012 Jan; 24 Suppl 2():S3-11. PubMed ID: 22245806
[TBL] [Abstract][Full Text] [Related]
32. Pomalidomide in the treatment of relapsed multiple myeloma.
Forsberg PA; Mark TM
Future Oncol; 2013 Jul; 9(7):939-48. PubMed ID: 23837756
[TBL] [Abstract][Full Text] [Related]
33. Multiple myeloma: improved outcomes with new therapeutic approaches.
Eshaghian S; Berenson JR
Curr Opin Support Palliat Care; 2012 Sep; 6(3):330-6. PubMed ID: 22871979
[TBL] [Abstract][Full Text] [Related]
34. Novel drug combinations for the management of relapsed/refractory multiple myeloma.
Usmani SZ; Lonial S
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S71-7. PubMed ID: 25486960
[TBL] [Abstract][Full Text] [Related]
35. Pomalidomide in heavily pretreated refractory multiple myeloma: a case report.
Palmas A; Piras G; Uras A; Asproni R; Murineddu M; Monne M; Stradoni R; Latte G
Future Oncol; 2017 Feb; 13(5s):7-9. PubMed ID: 28116939
[TBL] [Abstract][Full Text] [Related]
36. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
Sonneveld P; Hajek R; Nagler A; Spencer A; Bladé J; Robak T; Zhuang SH; Harousseau JL; Orlowski RZ;
Cancer; 2008 Apr; 112(7):1529-37. PubMed ID: 18300257
[TBL] [Abstract][Full Text] [Related]
37. Safety and tolerability of pomalidomide-based regimens (pomalidomide-carfilzomib-dexamethasone with or without cyclophosphamide) in relapsed/refractory multiple myeloma and severe renal dysfunction: a case series.
Richter J; Biran N; Duma N; Vesole DH; Siegel D
Hematol Oncol; 2017 Jun; 35(2):246-251. PubMed ID: 27018162
[TBL] [Abstract][Full Text] [Related]
38. Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden.
Borg S; Nahi H; Hansson M; Lee D; Elvidge J; Persson U
Acta Oncol; 2016 May; 55(5):554-60. PubMed ID: 27123742
[TBL] [Abstract][Full Text] [Related]
39. Lenalidomide: new drug. Myeloma: many questions remain unanswered.
Prescrire Int; 2008 Dec; 17(98):230-2. PubMed ID: 19422142
[TBL] [Abstract][Full Text] [Related]
40. Pomalidomide for patients with multiple myeloma.
Gras J
Drugs Today (Barc); 2013 Sep; 49(9):555-62. PubMed ID: 24086951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
